The possibility of catching severe COVID-19 disease with cardio-renal manifestation after the first dose of the BNT-162b2 vaccine: A case report
<p>Introduction: Since November 2019, coronavirus disease 2019 (COVID-19) has continued to spread across the world in an unpredictable way. In December 2020, the US Food and Drug Administration (FDA) issued Emergency Use Authorizations for two mRNA-based vaccines for prevention of COVID-19 inc...
Saved in:
Main Authors: | Randa Tabbah (Author), Nagi Azzi (Author), Rachoin Rachoin (Author) |
---|---|
Format: | Book |
Published: |
Journal of Cardiovascular Medicine and Cardiology - Peertechz Publications,
2021-07-06.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Diagnosis of Angioimmunoblastic T Cell Lymphoma After Receiving First Dose of Pfizer/BioNTech (BNT162b2) Vaccine: A Case Report
by: Jai Kumar Khatri MD, et al.
Published: (2024) -
B and T cell responses to the 3rd and 4th dose of the BNT162b2 vaccine in dialysis patients
by: Younes Bathish, et al.
Published: (2024) -
Reactive arthritis following COVID-19 vaccination with BNT162b2
by: Emily Lebowitz, MD, et al.
Published: (2022) -
Active Covid-19 infection and transmission after the first dose of the BNT162b2 mRNA vaccination in Saudi Arabia: A case report
by: Asem A. Allam, et al.
Published: (2021) -
Medium-term immunogenicity of three doses of BNT162b2 and CoronaVac in Hong Kong neuromuscular disease patients
by: Michael Kwan Leung Yu, et al.
Published: (2024)